Today: 11 June 2026
Browse Category

TSX:BB.TO 21 May 2026 - 25 May 2026

BlackBerry Rallies 19%; Quiet Holiday Week Could Test QNX Momentum

BlackBerry Surges, Eyes on Tuesday for Next Move

BlackBerry’s Toronto shares hit a 52-week high Monday, trading at C$11.47 before settling at C$11.37. U.S. shares remain frozen at $7.91 with the NYSE closed for Memorial Day. The stock jumped 28% last week after strong Q4 results and a new record for QNX revenue. CIBC raised its price target to US$8.50, citing momentum in BlackBerry’s QNX and secure communications units.
25 May 2026
··
BlackBerry Rallies 19%; Quiet Holiday Week Could Test QNX Momentum

BlackBerry Rallies 19%; Quiet Holiday Week Could Test QNX Momentum

BlackBerry’s U.S. shares surged 18.95% to $7.91 on Friday, with Toronto shares up 18.52% to C$10.88, as trading volume topped 57 million. The jump followed news that BlackBerry’s AtHoc platform secured 2026 FedRAMP High re-certification and QNX is set to appear at the Robotics Summit in Boston. Fourth-quarter revenue rose 10% to $156 million, with QNX posting record sales.
24 May 2026
···
BlackBerry Stock Jumps as U.S. Security Win Fuels Its Software Comeback

BlackBerry Stock Jumps as U.S. Security Win Fuels Its Software Comeback

BlackBerry’s Toronto shares closed up 7.9% after its AtHoc crisis-communications platform received renewed U.S. government cloud-security certification. Executives highlighted growth prospects for the QNX embedded-software unit at a CIBC investor conference. The U.S.-listed stock rose about 7.5%. Management cited recent cost cuts and a move to positive cash flow.
21 May 2026
···

Stock Market Today

  • Ideaya Biosciences Stock Drops 10% Amid $300M Fundraising Despite Bullish Outlook
    June 10, 2026, 10:30 PM EDT. Shares of Ideaya Biosciences ($IDYA) fell 10% to around $27 following the announcement of a $300 million stock offering priced at $27 per share, diluting existing shareholder value. The biotech firm had surged 13% earlier due to promising oncology trial results presented at ASCO. Analysts from Citizens reaffirmed a Market Outperform rating and a $45 target, citing robust pipeline developments and collaborations, including a deal with Roche on a novel oncology drug combination. Positive clinical data showed a 37% response rate in uveal melanoma, substantially outperforming standard care. The cash raise aims to advance multiple cancer trials, ensuring a solid financial runway despite near-term stock pressure from dilution.

Latest articles

Tech stocks slide after hours, Oracle’s AI spending draws focus

Tech stocks slide after hours, Oracle’s AI spending draws focus

11 June 2026
Semiconductor stocks plunged 3.6%, dragging the S&P 500 technology sector into correction territory—down 11% from its June 2 record—as investors punished AI-linked companies like Oracle and Super Micro Computer for heavy spending and capital raises, signaling a shift in risk appetite amid rising inflation and escalating U.S.-Iran tensions.
Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

11 June 2026
Murphy USA soared 10.04% to $612.16 as investors seized on Casey’s General Stores’ stronger-than-expected fuel margins, spotlighting sector-wide pump profitability; with Murphy’s own first-quarter fuel contribution up 40.6% and margins at 35.0 cents per gallon, the stock’s jump reflects bets that high margins will persist, though volatility in fuel prices remains a key risk.
Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

11 June 2026
Sky Quarry soared 22.44% to $1.91 on record volume, then jumped to $2.38 after hours, as investors bet on a June refinery restart after repairs and a feedstock shortage crushed Q1 revenue to $383; with just $66,828 in cash and “substantial doubt” about its ability to continue, the stock’s fate hinges on hitting its June production target.
Go toTop